Author Archive: George Goodno

George Goodno

George is the Director of State Policy Communications at BIO and enjoys the opportunity to advocate for and educate audiences about the positive societal and economic impact of the bioscience industry. Another great aspect of his job is getting to work with BIO’s broad network of state bioscience associations to help advance legislative and regulatory initiatives that will continue to improve this high-skill, high-wage industry. In his spare time, he enjoys running, skiing, hiking, gardening, and most of all, spending time with his awesome wife and two daughters.

Follow him on Twitter @ggoodno

 

Latest Posts

The New Road to IPO in the Age of the JOBS Act

President Obama

Not surprisingly, sessions discussing the topic of IPOs at this year’s BIO Investor Forum, tend to fill the room. Furthermore, it should surprise no one that this year’s IPO discussions were upbeat. That is mostly attributable to the dramatically higher number of IPOs that have already occurred this year. Furthermore, according to Jeff Baumel, moderator of a panel covering this very topic, deals are closing faster this year – with a median time of just Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Successful Public-Private Partnerships

According to BayBio, biomedical companies that can harness the power of patient groups will get medicines, devices and diagnostics to market faster, cheaper and smarter, helping patients and rewarding investors. Gail Maderis, ‎President & CEO at BayBio, debuted their preliminary whitepaper entitled “Successful Public-Private Partnerships” today at the 2013 BIO Investor Forum. BayBio surveyed nearly 100 biotech and foundation CEOs, vice presidents of research, directors of patient advocacy and others across the United States. Following Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

The New Demand for Biotech Industry Talent

scientists115x76

Biotechnology is a multi-disciplinary field involving the integration of knowledge and skills drawn from numerous disciplines, such as microbiology, biochemistry, genetics, molecular biology and chemistry. Traditionally, the field of biotechnology has required a workforce with a wide array of highly specialized skills and training. Interestingly though, a shift has begun to take place, favoring people with interdisciplinary academic training who can support more than one project team and work across multiple areas. On September 10, Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: ,

BIO Welcomes Five New Board Members

Jim Greenwood

BIO elected five new members to its Board of Directors, voted upon at this year’s Board Meetings, held last week in Washington, DC. The following individuals were elected to the Health Section Governing Board: Francois Nader, President & CEO of NPS Pharmaceuticals, Inc. Anna Protopapas, President of Millennium: The Takeda Oncology Company Allen Waxman, Senior Vice President and General Counsel of Eisai, Inc. Klaus Wilgenbus, Senior Vice President, Business Development & Licensing of Boehringer Ingelheim Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags:

Top Biotech States Ranked

We here at BIO prefer to stay away from ranking states. After all, every state is different. Bioscience economic development in a nation as large and diverse as the United States is as varied as the country itself. A complex array of factors influence the allocation of resources and the nature of bioscience industry development: Presence of Universities Talent in the workforce Climate and geography Sufficiency of business capital Historical economic influences Ultimately, these characteristics Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , ,